Changchun High-Tech Industry (000661.SZ): Clinical trials for the production of domestically manufactured drugs for injection using GenSci139 have been approved.
Changchun High-tech (000661.SZ) announcement, the company's subsidiary - Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "...
Changchun High-Tech Industry (000661.SZ) announced that its subsidiary, Changchun Gold Medal Pharmaceutical Co., Ltd. (referred to as "Gold Medal Pharmaceutical"), has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the clinical trial of injectable GenSci139 monotherapy in patients with advanced solid tumors.
Related Articles
The actual controller of Shenzhen Etmade Automatic Equipment (300812.SZ) intends to transfer 5% of the shares to Qianji Investment Agreement.
CH TIANBAO GP(01427): Hou Liang's term as an independent non-executive director has expired.
GREENTOWN CHINA (03900) enters into a real estate development entrustment management agreement with Hangzhou Zhongyi Jiangchen Property.
The actual controller of Shenzhen Etmade Automatic Equipment (300812.SZ) intends to transfer 5% of the shares to Qianji Investment Agreement.
CH TIANBAO GP(01427): Hou Liang's term as an independent non-executive director has expired.
GREENTOWN CHINA (03900) enters into a real estate development entrustment management agreement with Hangzhou Zhongyi Jiangchen Property.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
